Società Novartis AG Swiss Exchange

NOVNEE

CH0038459415

Prodotti farmaceutici

Consensus Analisti

Attività

Vendite per attività

Vendite per regione

Dirigenti

Amministratori

Classe di azioni

Azionisti

Partecipazioni

Coordinate società

Società del gruppo

Settore

Vendite per attività

Vendite per regione

Rating per Novartis AG

Revisioni EPS

Utili trimestrali - Indice di sorpresa

Settore Prodotti farmaceutici - Altri

Mercato chiuso - Swiss Exchange Altri mercati azionari 17:31:41 11/07/2024			Variaz. 5gg	Var. 1 gen.
99,59 ^CHF	+1,28%		+3,28%	+17,76%

11/07	Novartis chiuderà la struttura di ricerca tecnica di San Diego, California; 100 posti di lavoro interessati	MT
11/07	Borsa svizzera: chiude in rialzo, SMI +0,86%	AW

Novartis AG è uno dei leader mondiali nella progettazione, produzione e commercializzazione di prodotti farmaceutici. Le vendite nette (escluse le attività cessate) sono suddivise per area terapeutica come segue:
- oncologia (29,9%);
- immunologia (17,2%);
- malattie cardiovascolari, renali e metaboliche (14,1%);
- neuroscienze (8,9%).
Le vendite nette rimanenti (29,9%) derivano dalla produzione a contratto di prodotti farmaceutici.
Alla fine del 2023, Novartis AG aveva 33 siti di produzione in tutto il mondo.
Le vendite nette sono distribuite geograficamente come segue: Europa (33%), Stati Uniti (39,5%), Asia/Africa/Australasia (20,5%), Canada e America Latina (7%).

Numero di dipendenti: 76 057

CHF in Milioni	2022	Peso	2023	Peso	Delta
Established Brands 30,0 %	-	-	12 238	30,0 %	-
Oncology 29,9 %	-	-	12 213	29,9 %	-
Immunology 17,2 %	-	-	7 008	17,2 %	-
Cardiovascular, Renal and Metabolic 14,1 %	-	-	5 743	14,1 %	-
Neuroscience 8,9 %	-	-	3 633	8,9 %	-

CHF in Milioni	2022	Peso	2023	Peso	Delta
United States 39,5 %	16 860	34,9 %	16 139	39,5 %	-4,28%
Europe 18,9 %	10 469	21,7 %	7 704	18,9 %	-26,41%
Asia/Africa/Australasia 9,1 %	4 975	10,3 %	3 700	9,1 %	-25,63%
Germany 7,4 %	4 086	8,5 %	3 026	7,4 %	-25,94%
China 7,2 %	2 987	6,2 %	2 936	7,2 %	-1,73%
Canada and Latin America 7,0 %	3 709	7,7 %	2 854	7,0 %	-23,04%
Japan 4,2 %	2 106	4,4 %	1 729	4,2 %	-17,90%
France 3,8 %	2 156	4,5 %	1 572	3,8 %	-27,09%
Switzerland 2,9 %	926	1,9 %	1 175	2,9 %	+26,88%

Dirigenti	Titolo	Età	Da
Vasant Narasimhan CEO	Chief Executive Officer	48	01/01/05
Harry Werner Kirsch DFI	Director of Finance/CFO	59	01/01/03
Shreeram Aradhye CTO	Chief Tech/Sci/R&D Officer	62	16/05/22
Steffen Lang COO	Chief Operating Officer	57	01/04/17
Klaus Moosmayer CMP	Compliance Officer	56	01/12/18
Samir Shah IRO	Public Communications Contact	63	01/01/04
Simon Brown PRN	Corporate Officer/Principal	-	01/08/13
Kees Roks AUD	Comptroller/Controller/Auditor	61	01/05/22
Linda Kanitra PRN	Corporate Officer/Principal	-	-
Robert Kowalski HRO	Human Resources Officer	56	01/09/21

Amministratori	Titolo	Età	Da
Bill Winters BRD	Director/Board Member	62	01/01/13
Simon Moroney BRD	Director/Board Member	65	28/02/20
Hans Jörg Reinhardt CHM	Chairman	68	01/01/13
John Young BRD	Director/Board Member	60	07/03/23
Bridgette Heller BRD	Director/Board Member	62	28/02/20
Ton Büchner BRD	Director/Board Member	59	01/01/16
Charles Sawyers BRD	Director/Board Member	65	01/01/13
Nancy Andrews BRD	Director/Board Member	65	01/01/15
Patrice Bula BRD	Director/Board Member	68	28/02/19
Frans van Houten BRD	Director/Board Member	64	28/02/17

	Voto	Quantità	Flottante	Autocontrollo	Flottante totale
Azione A	1	2 189 930 497	1 866 336 959 ( 85,22 %)	233 443 766 ( 10,66 %)	85,22 %

Nome	Azioni	%	Valorizzazione
NOVARTIS AG 6,625 %	145 083 991	6,625 %	15 527 M CHF
Sandoz Family Foundation 4,070 %	89 135 960	4,070 %	9 540 M CHF
UBS Asset Management Switzerland AG 3,123 %	68 391 910	3,123 %	7 319 M CHF
MFS International Singapore Pte Ltd. 0,1917 %	4 198 717	0,1917 %	449 M CHF
State Street Global Advisors Ltd. 0,1666 %	3 648 139	0,1666 %	390 M CHF
Sjunde AP-fonden 0,1384 %	3 031 826	0,1384 %	324 M CHF
Eleva Capital LLP 0,1355 %	2 967 691	0,1355 %	318 M CHF
MFS International (UK) Ltd. 0,1354 %	2 965 075	0,1354 %	317 M CHF
Barings (UK) Ltd. 0,1310 %	2 868 212	0,1310 %	307 M CHF
Amundi Asset Management SA (Investment Management) 0,1084 %	2 373 632	0,1084 %	254 M CHF

Nome	Azioni	%	Valorizzazione
PRIMECAP Management Co. 0,5670 %	12 417 755	0,5670 %	1 322 M CHF
Dodge & Cox 0,5641 %	12 353 985	0,5641 %	1 315 M CHF
Eaton Vance Management 0,3314 %	7 258 381	0,3314 %	773 M CHF
Loomis, Sayles & Co. LP 0,2702 %	5 917 972	0,2702 %	630 M CHF
DFA Australia Ltd. 0,2625 %	5 748 542	0,2625 %	612 M CHF
Fiduciary Trust Company International 0,2603 %	5 700 550	0,2603 %	607 M CHF
U.S. Trust Company of Delaware 0,2273 %	4 977 839	0,2273 %	530 M CHF
Wellington Management Co. LLP 0,2096 %	4 589 350	0,2096 %	489 M CHF
Wells Fargo Bank NA 0,1826 %	3 997 877	0,1826 %	426 M CHF
The Ayco Co. LP 0,1397 %	3 059 361	0,1397 %	326 M CHF

Nome	Azioni	%	Valorizzazione
LUKB Expert Fondsleitung AG -	64 694	-	7 M CHF
Swiss Rock Asset Management AG -	19 614	-	2 M CHF

Nome	Azioni	%	Valorizzazione
NOVARTIS AG 6.63%	145 083 991	6.63%	15 527 183 237 $
MORPHOSYS AG 51.00%	19 235 376	51.00%	1 393 608 762 $
SANDOZ GROUP AG 2.99%	12 886 900	2.99%	466 659 005 $
NOVARTIS INDIA LIMITED 70.68%	17 450 680	70.68%	231 036 358 $
THIRD HARMONIC BIO, INC. 6.45%	2 642 762	6.45%	34 355 906 $
ERASCA, INC. 4.74%	12 307 692	4.74%	29 046 153 $
OCULIS HOLDING AG 4.11%	1 713 521	4.11%	20 476 576 $
MOLECULAR PARTNERS AG 4.74%	1 739 130	4.74%	12 618 658 $
PRECISION BIOSCIENCES, INC. 5.97%	413 581	5.97%	4 024 143 $

Novartis AG

Lichtstrasse 35

4056, Basel

+41 61 324 1111

http://www.novartis.com

Nome	Categoria e settore
Novartis Healthcare Pvt Ltd. Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar.	Pharmaceuticals: Major
Novartis Pharma AG Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis Investment Ltd.
Novartis Holding AG Novartis Holding AG Financial ConglomeratesFinance Part of Novartis AG, Novartis Holding AG is a Swiss healthcare company that provides solutions to address the evolving needs of patients worldwide. The company is based in Basel, Switzerland. Novartis Holding specializes in Managed Access Programs and is committed to the discovery, development, and marketing of innovative products to improve the well-being of all Canadians. The company prides itself on its commitment to diversity and to nurturing an inclusive and inspiring environment.	Financial Conglomerates
Novartis International AG Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland.	Pharmaceuticals: Major
Novartis Services, Inc.
Novartis Finance SA	Finance/Rental/Leasing
Novartis BioVenturesAG Novartis BioVenturesAG Investment ManagersFinance Part of Novartis AG, Novartis BioVenturesAG is an alternative investment manager. The company is based in Basel, Switzerland.	Investment Managers
Novartis Investments SARL Novartis Investments SARL Financial ConglomeratesFinance Novartis Investments SARL is an investment holding company with interest in medicines and pharmaceuticals sector. The company was founded on July 05, 2002 and is headquartered in Luxembourg.	Financial Conglomerates
Novartis Securities Investment Ltd. Novartis Securities Investment Ltd. Investment ManagersFinance Part of Novartis AG, Novartis Securities Investment Ltd. is an investment bank that offers investment advice. The company is located in Bermuda.	Investment Managers
Novartis Capital Corp. Novartis Capital Corp. Finance/Rental/LeasingFinance Novartis Capital Corp. engages in the manufacture of pharmaceutical products. The company is headquartered in East Hanover, NJ.	Finance/Rental/Leasing
Sandoz Pvt Ltd. Sandoz Pvt Ltd. Pharmaceuticals: GenericHealth Technology Part of Novartis AG, Sandoz Pvt Ltd. is an Indian company that develops, manufactures, and markets generic pharmaceutical products. The company is based in Mumbai, India. Sandoz was founded in 1995.	Pharmaceuticals: Generic
Novartis Investment Ltd. (2120)
Novartis Pharma GmbH Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.	Pharmaceuticals: Major
Sandoz GmbH Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria.	Pharmaceuticals: Major
Alcon Ophthalmika GmbH
EBEWE Pharma Ges.m.b.H. Nfg.KG EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria.	Pharmaceuticals: Major
NOVARTIS INDIA LIMITED	Pharmaceuticals: Major
Novartis UK Pension Scheme	Investment Managers

Rating Trading

Rating Investimento

ESG Refinitiv

Altri rating

Vendita

Buy

Raccomandazione media

Accumulate

Numero di analisti

Ultimo prezzo di chiusura

109,3 USD

Prezzo obiettivo medio

112,1 USD

Differenza / Target Medio

+2,59%

Consenso

Revisioni delle Stime

Calendario della società

Biotecnologia/Farmaceutici

Biotecnologia/Farmaceutici

Prodotti farmaceutici

Prodotti farmaceutici - Altri

	Variaz. 1 gen.	Capi.
ELI LILLY AND COMPANY	+60,25%	846 Mrd
NOVO NORDISK A/S	+38,56%	628 Mrd
JOHNSON & JOHNSON	-4,49%	360 Mrd
MERCK & CO., INC.	+18,30%	322 Mrd
ABBVIE INC.	+9,64%	297 Mrd
ASTRAZENECA PLC	+14,15%	240 Mrd
ROCHE HOLDING AG	+3,11%	224 Mrd
AMGEN INC.	+12,87%	173 Mrd
PFIZER, INC.	-0,45%	161 Mrd

Prodotti farmaceutici - Altri